A shift in macro conditions is driving deal volume across resilient subsectors, but regulatory scrutiny remains a key headwind.
Following a subdued 2024, healthcare M&A and financing activity is gaining momentum in 2025. Lower interest rates, stronger credit markets, and a return of private equity capital are fueling deal flow, particularly in scalable, tech-driven sectors. Corporates and sponsors are re-engaging with strategic acquisitions, but face a regulatory environment that is more active and complex than ever.
We discuss the market in detail, including the following trends, in our recent article "Healthcare M&A and Financing in 2025," which was published by LaingBuisson:
- Private equity is re-entering with focus on carve-outs, sponsor-to-sponsor deals, and consolidation in high-margin verticals.
- AI-driven healthtech, precision medicine, and aging care are leading the list of investor-favored subsectors.
- Venture capital is shifting toward later-stage companies with proven clinical and commercial traction.
- Antitrust scrutiny is intensifying across the US, UK, and EU, reshaping deal strategies and buyer profiles.
Click for a preview or return on July 1, 2025 for the full article.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
